← SynDRA
BMS-986020
SynDRA canonical compound SYN0039449 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | LPAR1 |
|---|
| Mechanism of action | lysophosphatidic acid receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- LPAR1 ANTAGONIST
- Lysophosphatidic acid receptor Edg-2 antagonist
- lysophosphatidic acid receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- ABCB4
- ABCC2
- ABCC3
- ABCC4
- CYP1A2
- CYP2B6
- CYP2C19
- CYP2C8
- CYP2C9
- CYP2D6
- CYP3A4
- KCNH2
- SLCO1B1
- SLCO1B3
Cross-references
Synonyms
- AP-3152 FREE ACID
- GQBRZBHEPUQRPL-LJQANCHMSA-N
- AP-3152 free acid
- UNII-38CTP01B4L
- 38CTP01B4L
- SCHEMBL344742
- GTPL9498
- EX-A866
- MolPort-044-616-249
- ZINC113624125
- AKOS030631907
- CS-5844
- AS-35060
- HY-100619
- FT-0700148
- J-690107
- Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-
- 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid
- 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl
- RefChem:120763
- MFCD30489743
- BMS-?986020
- orb1303303
- GLXC-10654
- BDBM50581550
- EBC-70054
- s3572
- BMS 986020 [WHO-DD]
- BMS-986020?
- NCGC00510489-03
- AC-36136
- BB165375
- T4016
- EN300-266226
- 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
- orb1686604
- T63439
- AM152 (sodium)
Look up BMS-986020 in the interactive SynDRA portal →